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Cardiac Repair and Regeneration: The Value of Cell Therapies
Acute myocardial infarction (AMI) is still a major public health problem 
worldwide, causing high rates of morbidity and mortality. In the United 
States, nearly one million patients suffer from AMI each year.1 In the UK, 
around 80,000 people died from coronary heart disease (CHD) in 2010.2
The current approach to the treatment of myocardial infarction 
involves early revascularisation with percutaneous coronary 
intervention (PCI) or coronary artery bypass grafting (CABG), followed 
by the medical management of atherosclerotic risk factors, late 
ventricular remodelling and cardiac arrhythmias.
Improvements in the treatment of AMI, especially use of reperfusion 
therapy, have led to larger numbers of survivors. In patients who 
would have survived despite reperfusion therapy, use of this 
treatment should lead to greater myocardial salvage and a reduced 
extent of ventricular injury in many. However, others who might not 
have survived previously may now do so, but with substantial left 
ventricular damage.3,4 The net consequence of these two opposing 
effects on the early and later risk of developing heart failure after AMI 
is uncertain.
Several clinical trials and registries, despite methodological 
differences, tend to agree that heart failure is a common occurrence 
after AMI, and there has been concern that an increasing pool of 
survivors of AMI might fuel an ‘epidemic’ of heart failure.5,6
Patients with chronic heart failure (CHF) have a mortality of 20 % within 
the first year after diagnosis.2 CHF accounts for roughly 70,000 deaths in 
the UK each year, corresponding to an average of 190 deaths per day.2
Despite recent advances in medical and device therapy and 
improvements in care over the past 20 years, the outlook for patients 
with heart failure remains poor, and survival rates are worse than 
those for bowel, breast or prostate cancer.7–9 Therefore, any new 
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treatment modality that benefits heart failure patients has the 
potential to result in a dramatic improvement in health outcomes and 
substantial cost savings for the community.
Ventricular remodelling after AMI involves replacing a significant 
amount of cardiomyocyte cell mass with fibrotic tissue, which results 
in contractile dysfunction. This degenerative process is not always 
irreversible; depending on the extent of damage and age of the subject, 
some spontaneous regeneration of the cardiac muscle may occur, 
which might be of key importance in the next generation of treatment 
modalities for such a severe and frequently deadly condition. The identity 
of the stem cells involved in cardiac repair is, however, still uncertain. 
Several novel treatment strategies are emerging, aiming at each stage 
of the pathological remodelling process, including stem cell treatments, 
paracrine signalling, microRNA-modification of key signalling events and 
tissue engineering. Cardiomyoplasty and stem cell therapy are generating 
great expectation to treat different types of cardiac diseases, including 
AMI, refractory angina and CHF. Effective medical treatments of these 
conditions will produce crucial improvement in overall health outcomes 
and substantial cost savings for the National Health Service (NHS).
Pathophysiology of Myocardial Infarction
Myocardial ischaemia may result from either a rise in metabolic demand or 
a reduction of oxygen and nutrient supply to the myocardium. Myocardial 
infarct occurs if the demand/supply mismatch is enough to trigger 
cellular necrotic and apoptotic mechanisms within cardiomyocytes. 
Several conditions are associated with an increased myocardial metabolic 
demand, such as severe hypertension, severe aortic stenosis, other 
valvular pathologies and low cardiac output syndromes. Not only do 
these conditions increase the metabolic demand, but they also have the 
capability to reduce the coronary perfusion by lowering the mean aortic 
pressure. Infarction can also be caused by other conditions that are 
characterised by thromboembolic or atherosclerotic stenosis/occlusion 
of coronary arteries, leading to ischaemia primarily by decreasing the 
delivery of oxygen and nutrients to the myocardium.10
Myocardial Repair after Myocardial Infarction
There are several cellular changes that occur in the myocardium 
following myocardial infarction. During the first 6–12 hours, a process 
of coagulative necrosis occurs, and the fibres at the periphery of 
the infarct become elongated and narrowed with signs of vacuolar 
degeneration. Concomitantly, oedema and neutrophils are observed 
in the intercellular spaces. This process lasts for 3 to 4 days. Following 
this stage, the necrotic myocytes are removed by macrophages, 
which may be actively phagocytic for 7 to 10 days. Finally, granulation 
tissue with loose collagen fibres and copious capillaries commence 
the healing and repair processes, in which the necrotic cardiac 
muscle cells are replaced by a collagen scar.10
Cardiac Regeneration and Cell Therapy
The heart, which had been considered as a terminally developed organ 
with no potential for regeneration in post-natal life, has recently been 
recognised to possess some intrinsic reparability. Currently, there are 
two complementary theories about the process of intrinsic repair in 
the heart after an ischaemic injury: (1) cardiomyocytes re-enter the cell 
cycle and start the process of proliferation, regeneration and repair of 
the necrotic tissue;11,12 and (2) certain endogenous cardiac stem cells 
undergo growth and differentiation, regulated either by secreted 
inflammatory factors or autocrine regulation.13,14 Both mechanisms 
may be involved in the process of heart regeneration.15 Currently, the 
research focus is on how to translate the preclinical cell-based results 
into effective clinical treatment. In order to repair the human heart, 
it is crucial to identify the appropriate cell type and optimal route to 
deliver it. The selected cells should be able to differentiate into mature 
cardiomyocytes and achieve electrical integration with mechanical 
coupling. They should also have the capability to repair the heart via 
paracrine effects. Importantly, delivery of such cells should be done 
with careful consideration of the risks and benefits to the patient. 
Possible delivery methods include intravenous, intracoronary or 
intramyocardial.16 In selecting appropriate cells, one needs to know 
each cell’s individual potential: its regenerative activity (ESC, iPSC, 
and endogenous cardiac stem cells), paracrine effects (MSC) and 
angiogenesis activity (endothelial precursors).
Endogenous Cardiac Progenitors
There are three different embryonic cardiac cell precursors: the 
cardiac mesoderm; the neural crest cells; and the pro-epicardial 
territory. Each of the original precursors will turn into different cardiac 
structures, as follows. (1) Cardiac mesoderm becomes endocardial 
cells, atrial myocytes and ventricular myocytes. (2) Cardiac neural 
crest becomes aorta smooth muscle cells and autonomic nervous 
system. (3) Pro-epicardium becomes smooth muscle of coronary 
arteries, fibroblasts, endothelium of coronary arteries.17–19
Recently, multipotent stem cells were identified in each one of the 
layers of human blood vessels. Myogenic endothelial cells (MECs) 
are located in the intima of blood vessels, whereas pericytes and 
adventitial cells (ACs) are located in the media and adventitia, 
respectively. MECs and pericytes have the capability to regenerate 
myofibres in dysfunctional skeletal muscles and to improve cardiac 
contractility following AMI.19
Recently, cardiogenic progenitor cells (CPCs) were detected in the adult 
heart. It is still not completely clear whether CPCs originate from the 
bone marrow, or there are populations of embryonic cells localised in 
the right atrium and right ventricle. Also, there is still ongoing research 
to determine the participation of these cells in the physiological turnover 
of cardiac myocytes and vascular endothelial cells in the absence of 
myocardial injury.20 CPCs represent 1 % of the total cell population in the 
heart and are divided into three groups so far identified (c-Kit+, Sca-1+ 
and ISL-1+ cells) according to the expression of membrane markers.20 
c-Kit+ cardiogenic stem cells express pluripotency, clonogenicity and 
self-renewal capabilities, and differentiate into myogenic, vascular 
endothelial and smooth muscle lines in vitro. These cells can regenerate 
the ischaemic myocardium in animal models.21,22 The group of CPCs 
expressing Sca-1+ interact with a homogeneous cell population in foetal 
and adult human hearts and show self-renewal properties together with 
active participation in cell signalling and cell adhesion.23
It is possible to differentiate Sca-1+ CPCs into cardiomyocytes by 
using 5-azacytidine. 5-Azacytidine is similar to cytidine, a nucleoside 
found in either DNA or RNA. The mechanism of action of this drug is 
through inhibition of the enzyme methyltransferase. 5-Azacytidine is 
incorporated into the structure of DNA and RNA instead of cytidine, 
inhibiting the synthesis of proteins within the cells.24 Additionally, 
the activation of extracellular signal-related kinases (ERK) by 
5-azacytidine seems to trigger the differentiation of human MSCs into 
cardiomyocytes in vitro.25 In vitro differentiation to cardiomyocytes 
appears to involve the receptor for bone morphogenic proteins 
like BMPR1A.26 Differentiated murine Sca-1+ cells can be detected 
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as mature cardiomyocytes after intravenous transfusion following 
myocardial ischaemia and necrosis in rats.26
A group of stem cells is found in the hearts of newborn mice, rats 
and humans. Neonatal mouse hearts have cells that express the 
transcription factor ISL-1 together with two more factors: Nkx2.5 and 
GATA4, which are crucial transcription factors that participate actively in 
the initial stages of cardiogenesis, but don’t express either c-Kit or Sca-
1.26,27 These cells can differentiate into cardiomyocyte phenotypes with 
intact calcium cycling. They produce action potentials when cultured 
together with neonatal myocytes.27,28 These findings allow the study of 
the molecular pathways linked to the differentiation of ISL-1+ cells into 
the different lineages in either postnatal or embryonic hearts. The limited 
capacity of human cardiomyocytes to regenerate in vivo is responsible 
for the development of heart failure after infarction. Understanding the 
molecular mechanisms involved in the differentiation of the embryonic 
heart is of crucial importance in the design of effective regenerative 
stem cell therapies to treat patients with cardiac injury.
Selection of Cell Types
There are two important mechanisms by which stem cells may work. 
(1) Paracrine effect of the cells: SKMs, BMMNCs and MSCs produce 
several cytokines and growth factors that increase angiogenesis, 
reduce apoptosis, decrease fibrosis and induce cardiac regeneration. 
Ischaemic patients can especially benefit from the paracrine effect, 
which enhances perfusion.29–31 (2) Trans-differentiation of the stem 
cells’ phenotypes into cardiomyocytes and replacement of injured 
cells, increasing the contractility of the injured tissue.
Bone marrow MSCs, adipose-tissue-derived stromal cells and 
pericytes are known to produce cardio-protective cytokines that 
could be enhanced by genetic engineering.30–32 These cells also have 
immunosuppressive properties, which allows their usage as potential 
allogenic drugs.33 Additionally, the cell factors can induce regeneration 
from myocardial niches of tissue-resident stem cells. The paracrine 
effect alone would not be enough to relieve severe heart failure 
with extended scars as it would require cardiac regeneration to 
complete the healing process. The cells should be able to contract 
and coordinate each other through Connexin-43, a protein involved in 
the myofibrillar coupling structure, thus avoiding lethal arrhythmias.34
Cardiac-committed stem cells could be extracted from endomyocardial 
biopsies or during CABG, expanded in vitro and reinjected. Current 
clinical human trials, such as Stem Cell Infusion in Patients with 
Ischaemic Cardiomyopathy (SCIPIO: cells harvested from right atrial 
appendage during CABG, which uses c-Kit + CSCs) and Cardiosphere-
derived Autologous SCs to Reverse Ventricular Dysfuntion (CADUCEUS: 
endomyocardial biopsy, which uses CDCs), have been showing 
promising results.35,36 In these trials, the cells expanded in vitro are 
injected into the coronary arteries in the catheterisation laboratory. 
In contrast, the Autologous Human Cardiac-derived Stem Cell to Treat 
Ischaemic Cardiomyopathy (ALCADIA) trial involves the delivery of 
the cells into the myocardium during CABG. Cardiac-derived stem 
cells are extracted from endomyocardial biopsies, expanded and 
then delivered to the heart during CABG surgery by intramyocardial 
injections then a biodegradable gelatin hydrogel sheet containing 
fibroblast growth factor is implanted on the epicardium.37 The ongoing 
problem is to clarify the characterisation of the cell phenotypes, as 
current phenotypic differences could correspond to the same cell in a 
different stage of development.38
The CADUCEUS trial uses a mixed population of stem cells 
denominated by cardiospheres of which mesenchymal stem cells are 
a big proportion.39,40 The SCIPIO trial works with c-Kit cells; whereas 
ALCADIA uses a mixed population extracted from endomyocardial 
biopsies and cultured for a month.
Within the pool of pluripotent stem cells, human ESCs could be 
committed toward cardiac lineage in vitro. These cells were obtained 
from disposed embryos in the context of assisted fertilisation. Results 
show good engraftment of differentiated cardiomyocytes, although the 
risk for teratomas and immune rejection needs further investigation.41–43
Another source of potential cells could be the pool of iPSCs that 
are selected from the patient’s somatic cells and reprogrammed to 
embryonic pluripotent status. Because of their oncogenic potential, 
they still need larger animal trials before they can be introduced to the 
market.44 MSCs and fibroblasts could be manipulated in vitro towards 
enhanced cardiopoiesis, thus increasing the intrinsic therapeutic 
benefit of the treated cells.45–47
Perivascular/Mesenchymal Stem Cells
The pericyte is the second most common cardiac cell type and its 
participation in cardiac pathophysiology and regenerative medicine 
is crucial.48 Pericytes are perivascular cells with contractile capability 
similar to those of the smooth muscle cells that wrap around blood 
vessels. These cells carry out several functions, including active 
participation in the development of vessels and their structural 
maintenance. Additionally, they can communicate with surrounding 
cells during the angiogenic process, either by direct contact or 
paracrine signalling.49 New insights into the use of pericyte transfusion 
as a potential new treatment for AMI showed that there was a 
significant improvement in the infarcted heart in a mouse model. The 
effect was achieved through lowering the threshold and the activation 
of an angiogenic program in the recipient model.50
The identification of pericytes in tissue is a complex process because 
there is no single reliable marker. Currently, several markers, such 
as NG2 (neuron-glial antigen 2), α-SMA (alpha smooth muscle actin) 
and PDGFR-β (beta-type platelet-derived growth factor receptor), are 
used, each staining a subset of pericytes. Additionally, CD146 stains 
pericytes and a subset of endothelial cells; CD34 stains endothelial and 
progenitor cells; and CD31 and CD144 stain mature endothelial cells. 
Histologically, pericytes are identified as cells positive for CD146 but 
negative for endothelial markers such as CD34, CD31 or CD144. The 
NG2 marker is a chondroitin sulphate proteoglycan that can be found on 
the surface of pericytes and a small subset of glial and endothelial cells 
and is expressed by SMA-negative pericytes, either in micro-vessels 
or in the intimal layer of large vessels.51 α-SMA is present in vascular 
smooth muscle cells and in pericytes. This marker was identified in the 
microfilament bundles responsible for pericyte contractile functions.52 
PDGFR-β is a useful abundant pericyte marker.53 Pericytes from mice that 
have abnormal PDGFR-β receptors exhibit micro-vascular abnormalities 
leading to lethal micro-haemorrhages and oedema.54 CD146, also 
known as Mel-CAM, MUC18, A32 antigen and S-Endo-1, is a specific 
membrane glycoprotein that can function as a Ca2+ independent cell 
adhesion molecule with participation in heterophilic activity between 
cells. CD146 is part of the immunoglobulin gene superfamily.55 CD34 is a 
trans-membrane protein expressed in either haematopoietic progenitor 
cells or vascular endothelial cells. In addition, CD34 takes an active part 
in the regulation of cell migration and differentiation.56
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Pericytes have been identified in several human organs, including 
skeletal muscle, pancreas, adipose tissue and placenta, using 
markers such as CD146, NG2, and PDGFR-β and absence of 
haematopoietic, endothelial and myogenic cell markers.57 Recent 
research demonstrated that human pericytes that are located 
around capillaries and micro-vessels can produce MSCs while in 
culture. Additionally, during the process of vascular regeneration and 
under the effect of growth factors, adventitial cells can undergo a 
phenotypic trans-differentiation into pericyte-like cells (see Figure 1).58 
Furthermore, there is clear evidence that pericytes contribute to 
cardiac repair by down-regulating immune cells via interaction with 
immunomodulatory cytokines and growth factors, following pericyte 
injection into ischaemic tissues.59
Clinical Applications
Current treatment protocols for AMI focus on reducing myocardial 
necrosis and irreversible damage by improving perfusion to the ischaemic 
area via medical or mechanical treatment such as CABG or PCI.60–62
The new potential cell-based treatments to deal with AMI derive from 
animal research in which mononuclear cells from bone marrow or 
peripheral blood were used in cardiac repair.63–68 Ongoing research in 
cardiac developmental and stem cell biology, as well as recent results 
from clinical trials SCIPIO and CADUCEUS using resident cardiac stem 
cells, have improved our understanding of in situ heart stem progenitor 
cells.69,70 The first non-randomised trials in humans showed that there 
was an improvement in cardiac function after the infusion of bone 
marrow stem cells and progenitor stem cells into the myocardium 
affected by the infarction.71–75 The stem cell types involved in the 
repair of cardiac tissue were first characterised by Stamm’s group in 
2003, when the infusion of CD133+ progenitor cells extracted from 
haematopoietic tissues were applied into the ischaemic cardiac 
myocardium. The result of this treatment was an improvement in the 
general revascularisation process.76 The first randomised multicentre 
trial in 2009 studied patients with severe left ventricular dysfunction as 
a consequence of AMI. The patients, who were infused with selected 
CD34+ and CXCR4+ cells and non-selected mononuclear cells into the 
lumen of their coronary tree, saw significant improvement in their left 
ventricular ejection fractionafter 6 months.77 The mechanism of action 
of such treatment seems to be either an increase in the angiogenesis 
activity and/or trans-differentiation of the cells into myocytes.78 The 
paracrine secretion of cytokines and other factors also increases 
vascular growth, favours cardiac repair and reduces local fibrosis.79 
Latest evidence from trials shows that adult bone marrow stem cell 
treatment significantly improves cardiac function in post MI patients 
and there is no evidence of any increase in morbidity or mortality in 
this treated group of patients.80 Research into more effective stem cell 
treatments allowed the isolation of neonatal and ischaemic myocardial 
cells expressing the c-Kit, MRD-1, ISL-1 or Sca-1 stem cell markers but 
no haematopoietic cell markers.26,81 The number of these cells increased 
after an AMI, suggesting an active role of these cells in cardiac repair.82
Application in Acute Myocardial Infarction with 
Concurrent CABG
Intra-myocardial injection of BMMNCs during CABG is shown to have 
improved outcomes compared with those of CABG alone.83 The aim of 
treating patients with stem cells after or during CABG following an episode 
of acute MI is to reduce later remodelling, which is known to have a 
negative impact on long-term outcomes.83 Such treatment is carried out 
by the interventional cardiologist and consists of delivering BMMNCs into 
the new coronary bypass graft. Unfortunately, there is still a need for more 
randomised trials to assess the potential benefits currently observed.83–85 
Patients with poor left ventricular function undergoing CABG seem 
to be better at 6 months post-operative if trans-epicardial injection of 
CD133+ cells was performed intraoperatively.84,85 These observations likely 
result from the angiogenic potential of cells rather than cardiomyocyte 
regeneration, since the CD133+ marker is expressed in the membrane of 
the endothelial cells. The PRECISE (Percutaneous Robotically-enhanced 
Coronary Intervention) trials use adipose-tissue-derived cells collected 
with lipo-aspiration from patients at the time of surgery. These cells are 
subsequently reinfused into the endocardium of the left ventricle. The 
final results of this technique are still pending.86
Application in Refractory Angina
A second treatment indication under investigation is for refractory 
angina (angina caused by coronary insufficiency in the presence of 
coronary artery disease that cannot be controlled by a combination 
of medical therapy, angioplasty and coronary bypass surgery), which 
would involve stem cell treatment alone or complemented with 
surgery. The aim in this subset of patients would be to use the different 
cell types as carriers of multiple cytokines and growth factors in order 
to induce angiogenesis in the affected territory and thus relieve 
ischaemic symptoms.87,88 Patients with refractory angina are currently 
under investigation in randomised trials to assess the apparent 
efficacy of catheter-based endoventricular injection of CD34+ cell 
progenitors following treatment with granulocyte colony stimulating 
factor for 5 days in order to induce autologous cell mobilisation.89 
Another randomised trial in the population of patients with refractory 
angina used trans-cathether endomyocardial injections of bone 
marrow unfractionated derived cells (MNC), which seem to have some 
efficacy in improving clinical parameters but more data is needed to 
find significant differences between the study arms.90
Application in Chronic Heart Failure 
A third application under research is the treatment of chronic heart 
failure patients in whom the aim is to regenerate areas of non-contractile 
myocardial fibrosis to achieve physiological and functional contractility.88 
Patients with chronic heart failure were included in the randomised, 
double-blinded placebo-controlled Myoblast Autologous Grafting trial. 
In addition to CABG, patients with severe left ventricular function 
underwent trans-epicardial injections of either autologous SKMs from 
a skeletal muscle biopsy or placebo injected in and around the scar.91 
Figure 1: Origin of Potential Stem Cells. Modified from an 
Original Drawing by Mirko Corselli58
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The preliminary results showed that there was no improvement in the 
ejection fraction at 6 months, but patients injected with 800 million 
cells presented a reduction in left ventricular volumes.91 The effects 
of such treatment on early post-operative rhythm abnormalities and 
left ventricular remodelling require further investigation. Intracoronary 
injection of bone-marrow-derived cells with and without CABG was 
tested in trials, but the results remain inconclusive.92,93 Regarding 
complications related to the type of cells, ventricular arrhythmia with 
myoblast implantation is the most worrisome. 
Future Prospects
The future of cardiac repair may rely on understanding the intrinsic 
mechanisms that regulate endogenous mobilisation and or delivery 
of these cells. Additionally, further studies are needed to develop 
a deeper understanding of the properties of pericytes and their 
potential to migrate to different tissues away from their perivascular 
location and to play an active role in cardiac repair after ischaemia.49 
This would involve a more modern interpretation of the pericyte’s 
role as a cell type involved in reducing the threshold for the activation 
of an angiogenic program in cardiac repair.50 It has been shown 
that exogenous administration of MSCs could stimulate cardiac 
precursors to proliferate and differentiate either by stimulation of the 
endogenous c-Kit+ CSCs or by improving cardiomyocyte cell cycling.94
Despite advancements in the field of cardiac regenerative biology, 
the perivascular cell compartment within the myocardium and its 
regenerative capability have not yet been studied in-depth. Pericytes 
and perivascular cells have a crucial role in physiological functions, as 
well as in the development of pathological conditions.95–98 Additionally, 
the participation of perivascular cells in post-injury tissue fibrosis 
has been shown in recent studies. The cardiac pericyte is the 
second most common cardiac cell type, and has started to attract 
attention in cardiac pathophysiology and regenerative medicine.99 
There is ongoing research on the role of pericytes in the activation of 
endogenous cardiac progenitors during cardiac repair.
Recently, there has been increasing interest in the study of transcription 
factors and signalling pathways involved in cardiac regeneration. This has 
triggered the investigation of thymosin β4, which is a protein that can 
reactivate the cells’ embryonic developmental potential and stimulate 
epicardial cell trans-differentiation to vascular regeneration.100–103
Conclusions 
Autologous cardiac cellular therapies appear to be safe and effective. 
The future of cardiac repair may rely on understanding the intrinsic 
mechanisms that regulate endogenous mobilisation and/or delivery of 
these cells. However, a considerable amount of work is to be performed 
before cardiomyoplasty (cell therapy of the heart) can be proposed as 
a routine treatment. The first question is which cells to use, as a variety 
of embryonic stem cells, reprogrammed adult stem cells, natural adult 
multi-lineage stem cells and lineage-committed stem cells are presently 
available. Arguably, the latter endogenous cardiomyogenic stem cells 
might be the best choice for cardiac repair. Ideally, these cells should be 
directly stimulated in situ, avoiding extraction, purification, culture and 
reinjection. It is therefore of uttermost importance to understand the 
identity and function of the cells that constitute the natural environment 
of cardiac progenitors and support their quiescence, self-renewal and 
activation. Additionally, further studies are needed to develop a deeper 
understanding about the properties of pericytes, as these cells have the 
potential to migrate to different tissues away from their perivascular 
location and play an active role in the activation of cardiac repair after 
ischaemia.49 This would involve a modern interpretation of the pericyte’s 
role as a cell type involved in reducing the threshold for the activation of 
an angiogenic program in cardiac repair.50 ■
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